Scarica l'app Stockscreener
21.90
0.41%
-0.09
Dopo l'orario di chiusura:
21.27
-0.63
-2.88%
Precedente Chiudi:
$21.99
Aprire:
$21.93
Volume 24 ore:
3.65M
Relative Volume:
0.68
Capitalizzazione di mercato:
$10.88B
Reddito:
$4.45B
Utile/perdita netta:
$205.00M
Rapporto P/E:
54.75
EPS:
0.4
Flusso di cassa netto:
$372.00M
1 W Prestazione:
-5.89%
1M Prestazione:
+1.39%
6M Prestazione:
+63.07%
1 anno Prestazione:
+80.69%
Intervallo 1D:
$21.71
$22.03
Intervallo di 1 settimana:
$21.60
$23.39
Portata 52W:
$8.02
$23.70
Elanco Animal Health Inc Stock (ELAN) Company Profile
Nome
Elanco Animal Health Inc
Settore
Telefono
877-352-6261
Indirizzo
450 ELANCO CIRCLE, INDIANAPOLIS
Confronta ELAN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
21.90 | 10.93B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
118.65 | 53.06B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.18 | 45.11B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.44B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.46 | 32.59B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
489.31 | 20.84B | 3.08B | 1.24B | 1.07B | 25.61 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-21 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Aggiornamento | Argus | Hold → Buy |
| 2025-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Iniziato | UBS | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Market Perform |
| 2024-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-19 | Iniziato | Jefferies | Buy |
| 2023-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-04-20 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Downgrade | Goldman | Buy → Sell |
| 2022-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-28 | Downgrade | Stifel | Buy → Hold |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-06-15 | Aggiornamento | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Iniziato | Stifel | Buy |
| 2021-03-22 | Downgrade | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Downgrade | Argus | Buy → Hold |
| 2020-11-09 | Downgrade | Barclays | Overweight → Underweight |
| 2020-08-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Ripresa | Credit Suisse | Neutral |
| 2020-08-04 | Ripresa | Goldman | Buy |
| 2020-07-27 | Downgrade | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Iniziato | Barclays | Overweight |
| 2019-08-26 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Neutral |
| 2019-03-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Iniziato | William Blair | Mkt Perform |
| 2019-01-23 | Iniziato | UBS | Sell |
| 2019-01-15 | Iniziato | Argus | Buy |
| 2018-10-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Elanco Animal Health Inc Borsa (ELAN) Ultime notizie
What downside risks could hit Elanco Animal Health Incorporated stockJuly 2025 PostEarnings & Fast Entry Momentum Trade Alerts - Newser
Will Elanco Animal Health Incorporated (5EA) stock outperform benchmarksOptions Play & Long-Term Investment Growth Plans - Newser
Why retail traders accumulate Elanco Animal Health Incorporated stockQuarterly Trade Summary & Weekly Watchlist for Consistent Profits - Newser
Why institutional investors increase stakes in Elanco Animal Health Incorporated stockWeekly Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
ELAN SEC FilingsElanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan
Channing Capital Management LLC Decreases Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Aquatic Veterinary Market Set to See Booming Growth 2025-2032 - openPR.com
Is Elanco Animal Health Incorporated stock vulnerable to rate hikesTrade Analysis Summary & Capital Efficiency Focused Strategies - Newser
SG Americas Securities LLC Sells 70,517 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Will Elanco Animal Health Incorporated stock beat international competitionMarket Trend Review & Expert-Curated Trade Recommendations - Newser
Elanco Animal Health (NYSE: ELAN) reports 10,314-share equity grant to director - Stock Titan
Elanco (ELAN) director reports 10,314-share deferred stock unit award - Stock Titan
Elanco (NYSE: ELAN) director R. David Hoover reports 10,314-share board equity award - Stock Titan
Elanco (ELAN) board director receives 10,314 deferred stock units in annual grant - Stock Titan
Elanco Animal Health (ELAN) director reports 10,314-share deferred stock grant - Stock Titan
Elanco (ELAN) director awarded 10,314 deferred stock units in Form 4 filing - Stock Titan
Can Elanco Animal Health Incorporated (5EA) stock retain market dominance - Newser
Legal & General Group Plc Boosts Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated $ELAN Position Raised by Brandes Investment Partners LP - MarketBeat
Can Elanco Animal Health Incorporated (5EA) stock deliver consistent EPS growthJuly 2025 Action & Momentum Based Trading Ideas - Newser
Will Elanco Animal Health Incorporated (5EA) stock boost dividends furtherTake Profit & Low Drawdown Investment Ideas - Newser
Is Elanco Animal Health Incorporated stock vulnerable to regulatory risksLong Setup & Weekly Watchlist of Top Performers - Newser
mRNA Vaccines for Animals Market Forecast 2025-2032: Emerging - openPR.com
Creative Planning Increases Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health (NYSE:ELAN) Stock Steady on Sector Review - Kalkine Media
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ensign Peak Advisors Inc Cuts Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health (ELAN) Is Up 8.6% After FDA Clears First Cat Screwworm Treatment – Has the Bull Case Changed? - Yahoo Finance
Can Elanco Animal Health Incorporated stock beat market expectations this quarterJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Rockefeller Capital Management L.P. Purchases 13,893 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Aug Decliners: Is Elanco Animal Health Incorporated stock dividend yield sustainableIPO Watch & High Return Trade Guides - BỘ NỘI VỤ
Elanco Animal Health Announces $245M Stock-For-Stock Acquisition Of Aratana Therapeutics - AOL.com
Elanco executive appointed as Neurizon’s board observer By Investing.com - Investing.com Canada
Elanco executive appointed as Neurizon's Board Observer - Yahoo Finance
Prudential Financial Inc. Sells 1,773,395 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know - Finviz
Top Animal Health Stocks: Elanco Leads with Innovation, Zoetis Faces Headwinds - Investing.com Canada
Analysts Set Expectations for ELAN FY2025 Earnings - MarketBeat
Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4) - Quantisnow
Elanco Animal Health (NYSE:ELAN) Rating Increased to Strong-Buy at KeyCorp - MarketBeat
Elanco (ELAN) Gains FDA Emergency Use Authorization for Credelio CAT - GuruFocus
Elanco (ELAN) Upgraded to Overweight, Targets $27 Per Share - GuruFocus
Elanco's Credelio CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats - Finviz
Elanco (ELAN) Gains FDA Emergency Use Approval for Cat Treatment - GuruFocus
Elanco stock rises after FDA emergency authorization for cat screwworm treatment - Investing.com Canada
Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats - Reuters
Elanco wins Overweight rating, Zoetis Sector Weight as KeyBanc reviews animal health space - Seeking Alpha
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats - Nasdaq
Elanco Animal Health Stock Is Undervalued: AnalystElanco Animal Health (NYSE:ELAN) - Benzinga
Elanco Animal Health rises as KeyBanc joins bull camp - TradingView
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Elanco Animal Health Inc Azioni (ELAN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):